Journal article
Screening and Prophylaxis to Prevent Hepatitis B Reactivation Introduction and Immunology
Joe Sasadeusz, Andrew Grigg, Peter D Hughes, Seng Lee Lim, Michaela Lucas, Geoff McColl, Sue Anne McLachlan, Marion G Peters, Nicholas Shackel, Monica Slavin, Vijaya Sundararajan, Alexander Thompson, Joseph Doyle, James Rickard, Peter De Cruz, Robert G Gish, Kumar Visvanathan
Clinics in Liver Disease | W B SAUNDERS CO-ELSEVIER INC | Published : 2019
Abstract
Current recommendations concerning hepatitis C virus (HBV) reactivation are limited, with nearly all guidelines focused on its occurrence in patients with hematological malignancies or some solid tumors, who are treated with immunosuppressive therapies. Few of the guidelines address reactivation in patients receiving immunosuppression with organ transplants or treatment with any of the many immunosuppressive agents in use today for the treatment of multiple different diseases, or in patients receiving the direct-acting antivirals used in the treatment of hepatitis C virus (HCV). This article covers the immunology of HBV reactivation, mechanisms of viral clearance, and recommendations for scr..
View full abstractGrants
Funding Acknowledgements
Meetings to discuss and develop recommendations presented in this manuscript and medical writing services provided in the preparation of this manuscript were funded by Gilead Sciences. Neither the medical writer or Gilead in any way influenced the content or the conclusions of the position paper. None of the authors had any direct financial support from Gilead Sciences or any other companies.